



WORLD ECONOMIC FORUM



Technology  
Pioneer  
2007

NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

### **AMORFIX LIFE SCIENCES APPOINTS AZIZ MEKOUAR AS A MEMBER OF BOARD OF DIRECTORS**

TORONTO, ON, January 4, 2008 – Amorfix Life Sciences is pleased to announce the appointment of Aziz Mekouar to the company's Board of Directors. "We are delighted to welcome Mr. Mekouar to our Board," said Graham Strachan, Chair of the Board of Amorfix. "His substantial business experience and leadership in global affairs and with the United Nations will be an important asset as Amorfix continues to pursue its strategic objective of becoming a world leader in the treatment and diagnosis of misfolded-protein and prion diseases."

Mr. Mekouar is currently the Ambassador of Morocco to the United States and participated in the negotiation of the Morocco/United States free trade agreement and the Millennium Challenge Account wherein the United States granted US\$697 million for Moroccan development projects. He has previously served as the Ambassador of Morocco to several European countries and other countries throughout the world. He has also served as Chairman of the Council and member of the United Nations Food and Agriculture Organization, which exercises functions dealing with world food and agriculture and related matters including their impact on human health.

Mr. Mekouar obtained his business degree from l'Ecole des Hautes Commerciales of Paris and frequently lectures on the economy and politics in universities and international conferences.

#### **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this*

*press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---